Lantus Solostar (Insulin Glargine)
Brand Names: Lantus Solostar
Methodology & AI Transparency ⓘ
Lantus Solostar (Insulin Glargine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Lantus Solostar (Insulin Glargine) represents a prescription brand-name insulin analog entry registered by sanofi-aventis U.S.
- 2 Real-world patient consensus: Branded insulin analog presentation of Insulin Glargine (sanofi-aventis U.S. LLC); generic reference RxCUI 285018.
- 3 Typical cash cost range: Dispensing cost comparison spans $452.33 mail/discount cash up to $1198.67 uninsured retail (federal NADAC $6.1643).
- 4 Top reported side effects / signs: Most commonly reported Lantus Solostar (Insulin Glargine) tolerability events: cutaneous rash (4.6%), pruritus (4.9%), peripheral edema (4.6%).
Ask our AI Specialists anything about Lantus Solostar (Insulin Glargine)
Lantus Solostar (Insulin Glargine) Mechanism, CYP450 Pathways & DailyMed Monograph
Lantus Solostar (Insulin Glargine) represents a prescription brand-name insulin analog entry registered by sanofi-aventis U.S. LLC with package codes 0088-2219, 0088-2220. Reviewed against 2025-06-02 FDA SPL standards (100 [iU]/mL Injection, Solution; Prescriber-supervised Insulin Glargine escalation or taper window), clinical deployment addresses 1 Indications and usage lantus: is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Lantus Solostar achieves therapeutic action via Insulin Glargine, engaging insulin analog physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 100 [iU]/mL Injection, Solution; Prescriber-supervised Insulin Glargine escalation or taper window (registered by sanofi-aventis U.S. LLC, NDC 0088-2219, 0088-2220), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Lantus Solostar ($1198.67 retail) with generic Insulin Glargine ($452.33 low cash).
Pharmacokinetic profiling of Lantus Solostar (Insulin Glargine) demonstrates an elimination half-life of Mean elimination half-life of 4 to 13 hours across adult Lantus Solostar (Insulin Glargine) dosing with Complete (~100%) parenteral systemic delivery for Lantus Solostar (Insulin Glargine) (100 [iU]/mL Injection, Solution) systemic bioavailability; clearance proceeds via dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of lantus solostar (insulin glargine), reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after lantus solostar (insulin glargine) administration.
Titration schedules for Lantus Solostar (Insulin Glargine) (100 [iU]/mL Injection, Solution → Prescriber-supervised Insulin Glargine escalation or taper window) require excluding contraindicated in patients with prior serious allergic response to lantus solostar (insulin glargine) (ndc 0088-2219); severe baseline organ impairment where insulin glargine accumulation exceeds safe therapeutic margins; real-world patient logs highlight nausea (8.7% of reports), headache (7.2% of reports), dizziness (6.2% of reports) alongside a 78.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Lantus Solostar (Insulin Glargine) in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Lantus Solostar (Insulin Glargine) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Lantus Solostar (Insulin Glargine) (NDC 0088-2219)
- Severe baseline organ impairment where Insulin Glargine accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (8 Reports)
Lantus Solostar (Insulin Glargine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lantus Solostar (Insulin Glargine))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in: What a 272-Participant Study Found The immunogenicity profiles of LY IGlar and IGlar are similar, with low levels of anti-insulin antibodies observed for both insulins. Diabetes, obesity & metabolism • 2022-06-15 • Phase III Randomized Trial | N = 272 | 87/100 | PMID 35187770 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee GL Glargine demonstrated similar immunogenicity, efficacy, and safety compared to Lantus over 26 weeks in patients with T1DM. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists • 2024-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38876181 ↗ |
| Can This Approach Help? Inside the Latest Research on Comparable real-world benefits and safety between LY2963016 insulin glargine and LY IGlar and IGlar had equivalent efficacy in glycaemic control and similar safety profiles in Chinese patients with T1DM, when used in combination with mealtime insulin lispro. Diabetes, obesity & metabolism • 2021-10-15 • Phase III Randomized Trial | N = 137 | 82/100 | PMID 34121308 ↗ |
Lantus Solostar (Insulin Glargine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $6.1643/unit (~$184.93/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1198.67 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $452.33 / mo | View logs ↓ |
| Ro Body & Metabolic Clinic (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $45.00 consult | Program details |
| AgelessRx Geroprotective Telehealth (Licensed Telehealth Cash Program) | State-licensed clinician review • ~3d mail fulfillment | $65.00/mo program | Program details |
Lantus Solostar (Insulin Glargine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Lantus Solostar (Insulin Glargine) RxNorm Concept ID | 285018 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $6.1643 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1198.67 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $452.33 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Lantus Solostar (Insulin Glargine) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Lantus Solostar (Insulin Glargine) (insulin analog) monograph synthesizing RxNorm 285018, openFDA FAERS signals, and $452.33–$1198.67 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Lantus Solostar (Insulin Glargine) community threads and patient logs by age, biological sex, dosage, and treatment duration.